Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE We aimed at clarifying the prevalence and clinical significance of MCM2 in HER2-amplified breast cancer subtype. 30358612

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer. 31662548

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE We show that both HER2 inhibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a newly identified covalent inhibitor of the transcription regulatory kinase CDK7. 31462705

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis. 31260379

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Although trastuzumab is one of the most effective therapeutic antibodies in HER2-overexpressing breast cancer, a significant number of patients do not benefit from this therapy due to inherent or acquired resistance mechanisms. 31804840

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE High KANK1 protein expression was correlated with smaller tumour size and HER2 negativity, and better outcome in terms of longer breast cancer-specific survival [p = 0.013, HR 0.7, 95% CI 0.536-0.893] and time to distant metastasis [p = 0.033, HR 0.65, 95% CI 0.51-0.819]. 31679074

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course. 31782032

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Postmenopausal women with stage I-IIIB HR+/HER2-   breast cancer were randomized to a 2-week lead-in of abemaciclib, anastrozole, or abemaciclib plus anastrozole followed by 14 weeks of the combination. 31615937

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections.The median age was 48 years. 31641845

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024). 31768816

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Docetaxel, cyclophosphamide and trastuzumab might be an option for primary systemic therapy in human epidermal growth factor receptor-2-positive early breast cancer. 31821506

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Transcription Factor Activator Protein 2γ (TFAP2C, AP-2γ) governs luminal breast cancer phenotype through direct and indirect regulation of ERα and ERα-associated genes, GATA3, FOXA1, EGFR, CDH1, DSP, KRT7, FBP1, MYB, RET, KRT8, MUC1, and ERBB2-genes which are responsible for the luminal signature in breast cancer. 31636386

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE From the discovery of endocrine and HER2 targeted therapies, to multigene arrays in chemotherapy for more specific patient selection, to radiomics and genetic subtyping, targeted therapies and precision medicine continue to push the management of breast cancer toward more individualized care. 31757313

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE The reliability of the presented biosensor for the selective screening of HER2-ECD was confirmed by analysing another breast cancer biomarker (CA15-3) and several human serum proteins. 31816682

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE In addition, TLR3 and TLR9 displayed significantly different expression levels in ER‑/PR‑negative breast cancer compared with the control tissues, while TLR5 expression was significantly reduced in HER2‑enriched breast cancer. 31789409

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EAC. 31809243

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 GeneticVariation BEFREE In postmenopausal women, Luminal A (OR 2.35, 95% CI 2.01-2.75), Luminal B HER2 negative (OR 1.81, 95% CI 1.46-2.25) and triple-negative subtype (OR 2.25, 95% CI 1.85-2.72) showed higher risk of breast cancer in obese II women. 31628583

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE <b>Expert opinion</b>: Pertuzumab is a key drug for the treatment of HER2-positive metastatic or early breast cancer. 30884986

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) breast cancer and are the standard of care in the first- or second-line setting. 31780379

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Sensitive and precise detection of ER, PR, and HER2 is of great significance for the diagnosis of breast cancer. 31665670

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE In human epidermal growth factor receptor 2-positive (HER2<sup>+</sup>) breast cancer, the incorporation of a dual HER2 blockade into neoadjuvant chemotherapy (NAC) has been shown to induce a higher rate of pathologic complete response (pCR). 31519449

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE Some proteins have been identified as prognostic factors for BC (Ki67, p53, E-cadherin, HER2). 31568637

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 GeneticVariation BEFREE The percentage of breast cancers with high TMB (more than 192 mutations per sample) was low (3.5-4.6%) in luminal and triple-negative cancers and higher (14.1%) in the HER2-positive subset. 31741177

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 Biomarker BEFREE OMclin1 and OMclin2 were evaluated for 646 postmenopausal patients with ER-positive/HER2-negative primary breast cancer with 0-3 involved lymph nodes in TransATAC. 31641007

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.800 GeneticVariation BEFREE To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. 31385051

2020